The Supreme Court on Monday threw out a lower court ruling allowing human genes to be patented, a topic of enormous interest to cancer researchers, patients and drug makers.
Is it just me, or has there been a plethora of “wins!” lately when it comes to food freedom, Big Pharma, and personal health? Not all is doom and gloom! I would like to think that we are slowly turning back the tide…bit by bit.
The court overturned patents belonging to Myriad Genetics Inc. of Salt Lake City on two genes linked to increased risk of breast and ovarian cancer.
Myriad’s BRACAnalysis test looks for mutations on the breast cancer predisposition gene, or BRCA. Those mutations are associated with much greater risks of breast and ovarian cancer.
The American Civil Liberties Union has been arguing that genes couldn’t be patented, a position taken by a district court judge but overturned on appeal.
The justices’ decision sends the case back down for a continuation of the battle between the scientists who believe that genes carrying the secrets of life should not be exploited for commercial gain and companies that argue that a patent is a reward for years of expensive research that moves science forward.
In 2010, a federal judge ruled that genes cannot be patented. U.S. District Judge Robert Sweet said he invalidated the patents because DNA’s existence in an isolated form does not alter the fundamental quality of DNA as it exists in the body nor the information it encodes.
Tiny URL for this post: http://tinyurl.com/d8jofqy